We have planned to start a randomized trial in which concurrent chemotherapy add to radiotherapy, concurrent hyperthermia add to radiotherapy, and combining all these three modalities for advanced cervical carcinomas.
Introduction
Cervical cancer is one of the most common tumors affecting women worldwide, both in incidence and mortalityl), and approximately 5,000 women die of this disease each year in Japan. Radiotherapy (RT) is widely accepted as the treatment of choice for patients with International Federation of Gynecology and Obstetrics (FIGO) Stage IIIB carcinoma of the cervix. There have been no substantial improvements in the treatment of cervical cancer since the advent of mega voltage irradiation in the 195052). Some clinicians have tried a number of experimental treatments designed to enhance the response of tumors to RT neutrons, radiation sensitizers, and chemotherapy delivered intra-arterially3).
Most these approaches have failed to improve the results over treatment with radiation alone.
Among five randomized trials demonstrating better results for patients with advanced cervical cancer by adding cisplatin to RT summarized by Thomas2), only one trial reports on the results of patients with FIGO Stage III-IV (n = 118)4). However, overall survival was not improved for FIGO Stage III-IV patients in that study. More recently, the results of trial by Dutch group5) demonstrated an increase in 3-year overall survival, from 27% to 51%, by adding hyperthermia (HT) to RT for cervical carcinoma patients in FIGO Stage IIB-IVA. We also reported that the 3-year overall survival and disease-free survival of patients in FIGO Stage IIIB treated with thermoradiotherapy (TRT) (58.2% and 63.6 %) were better than those of patients treated with RT (48.1% and 45%), but the difference was not significant6). The 3-year local relapse-free survival of patients treated with TRT (79.7%) was significantly better than that of patients treated with RT (48.5%).
Both concurrent chemotherapy and concurrent HT add to RT in cervical cancer, and therefore, combination of all these three modalities might lead to increased response rates and disease-free and overall survival. We have planned to start a randomized trial employing concurrent chemotherapy add to radiotherapy (CRT), concurrent hyperthermia add to radiotherapy (TRT), and combination of all these three modalities (CTRT) for advanced cervical carcinomas to confirm this hypothesis.
In this preliminary study, we evaluated the clinical response and acute toxicity of FIGO Stage IIIB cervical carcinomas patients treated with CTRT.
Materials and Methods
Between HT was delivered via a radiofrequency capacitive heating device (Thermotron RF-8, Yamamoto
Vinita Co., Osaka, Japan), which uses 8 MHz radiofrequency electromagnetic waves as a source of heat.
The output power ranged from 800 to 1500 W. The heating was performed as previously described7).
The electromagnetic power was applied between two external disk electrodes 25 and 30 cm in diameter placed on opposite sides of the pelvic region. The temperature of the tumor was measured in all patients by using a 4-point microthermo couple-sensor, which was inserted in advance into the tumor and rectum through a 21-gauge catheter, and left until the end of last HT session. HT was usually applied within 30 min after external RT for a total of 60 min independent of the pattern of temperature elevation once a week for a total of 5 sessions. The first heating was usually performed after the third or fifth fraction of external RT.
We defined the maximum tumor temperature (T max) as the maximum temperature obtained in the tumor during the steady state and at the end of treatment. The steady state was defined at 20 min after the start of HT.
All patients received an intravenous infusion of 40 mg of cisplatin per square meter of body-surface area over a 4-hour period once a week concomitant with RT and HT. Our treatment schedule combining all these three modalities for FIGO Stage IIIB cervical carcinomas was shown in Fig. 1 .
The response of the tumor to the treatment was eval uated as follows : complete response (CR) when no tumor was detected by physical examination or magnetic resonance imaging and cytologic or biopsy studies were negative for malignant cells for at least 1 month after treatment ; partial response (PR) when the tumor mass was reduced by > 50% ; no change (NC) when the reduction in the tumor mass was < 50%.
Toxicities were scored according to a modification of the Radiation Therapy Oncology Group (RTOG) morbidity scale8). Patients were examined every month after treatment. between temperature and initial response. Fig. 2a . Case 2. MRI image showed bulky cervical cancer (arrowhead) . Fig. 2b . There was no tumor 1 month after completion of treatment . 
Discussion
There is no curative surgical option for patients with locally advanced invasive carcinoma of the uterine cervix. Neither adjuvant surgery nor increasing doses of radiotherapy alone are likely to increase the rate of pelvic control in patients without the consequence of increased early and late complications9).
In our previous clinical study, TRT although tumor control was superior when patients underwent regional HT, 5-year survival was not statistically affected by HT. Notably, former study was not randomized. We also did not observe increased rate of distant metastases in contrast to data being reported by Sharma et al '2) .
A way to improve the treatment outcome by combining RT with chemotherapy has been reported by Wong et a113). They demonstrated for stage I, II, and III cervical cancer that chemoradiation (epirubicin 60 mg/m2) followed by adjuvant chemotherapy with epirubicin 90 mg/m2 administered at 4-week intervals for five additional cycles resulted in a significantly longer disease-free (P = 0.03) and cumulative survival (P = 0.04) as compared to standard pelvic RT. Moreover, the rate of distant metastasis was decreased (P = 0.012), although there was no difference in long-term local tumor control (P = 0.99).
On the other hand, the Gynecologic Oncology Group4) has explored the role of RT and concurrent chemotherapy with hydroxyurea, cisplatin and 5-fluorouracil. In their study, the rate of local recurrences was significantly lower with cisplatin-based regimen, whereas the rate of distant recurrences was only slightly reduced. These results suggested that the principal effect of cisplatin is radiosensitization. Morris et al.4 ) also reported that the addition of chemotherapy improved the control of pelvic disease and significantly increased overall survival rate (P = 0.004). However, as the most important problem, it is unclear whether the results of this study are applicable to all stages of cervical cancer, since only 30 percent of the patients had stage III or stage IVA disease. An improvement with respect to overall survival was not demonstrated for these FIGO Stage III-IV patients (P = 0.44).
HT-induced toxicity was previously reported by Nishimura et al."), who suggested that radiationinduced intestinal damage was enhanced by regional HT in patients with locally advanced colorectal cancer. Small bowel obstruction, intestinal fistula, and intestinal perforation were reported to increase in 2% to 19% of the patients with deep-seated malignant tumors by addition of regional HT to RT15). In our previous report6), 2 of 20 patients treated with TRT had Grade 3 toxicity. One patient had diarrhea during treatment and developed a sigmoid-ileum fistula 2 years after completing treatment . The second patient developed a colon obstruction 1.5 years after treatment.
The late toxicity of combined RT and cisplatin may be larger than that of RT alone . In a mouse model, an increase in bladder toxicity was found from adding cisplatin to radiotherapy16 
Conclusion
Treatment with CTRT was shown to be effective in patients with FIGO Stage IIIB cervical carcinoma.
In addition, a combination of all three modalities was well tolerated and had acceptable acute toxicity.
In order to explore the possibilities of further improvements in the treatment of cervical cancer , we have initiated in a study investigating whether CRT , TRT, and CTRT are feasible regimens.
